hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
A "flexible saw", consisting of a fine serrated link chain held between two wooden handles, was pioneered in the late 18th century (c. 1783–1785) by two Scottish doctors, John Aitken and James Jeffray, for symphysiotomy and excision of diseased bone, respectively. It was illustrated in the second edition of Aitken's Principles of Midwifery, or Puerperal Medicine (1785) in the context of a pelviotomy. In 1806, Jeffray published Cases of the Excision of Carious Joints, which collected a paper previously published by H. Park in 1782 and a translation of an 1803 paper by French physician P. F. Moreau, with additional observations by Park and Jeffray. In it, Jeffray reported having conceived the idea of a saw "with joints like the chain of a watch" independently very soon after Park's original 1782 publication, but that he was not able to have it produced until 1790, after which it was used in the anatomy lab and occasionally lent out to surgeons. Park and Moreau described successful excision of diseased joints, particularly the knee and elbow, and Jeffray explained that the chainsaw would allow a smaller wound and protect the adjacent muscles, nerves, and veins. While symphysiotomy had too many complications for most obstetricians, Jeffray's ideas about the excision of the ends of bones became more accepted, especially after the widespread adoption of anaesthetics.
India rejected Trump's offer to mediate India–China tensions. On February 13, 2025, Indian prime minister Narendra Modi became the fourth world leader to visit Donald Trump at the White House. In early 2025, deportations to Bhutan of Nepali-speaking Bhutanese refugees who had been settled in the US for nearly two decades resulted in statelessness of the deportees following their interrogation and expulsion from Bhutan upon arrival. Some of the refouled refugees, who had encountered largely minor legal issues in the US, were then arrested for illegal entry to Nepal upon seeking to re-enter the refugee camps they had previously inhabited before US resettlement.
Bioinspired materials, a manufacturing concept inspired by natural nacre, shrimp carapace, or insect cuticles, has led to development of bioprinting methods to manufacture large scale consumer objects using chitosan. This method is based on replicating the molecular arrangement of chitosan from natural materials into fabrication methods, such as injection molding or mold casting. Once discarded, chitosan-constructed objects are biodegradable and non-toxic. The method is used to engineer and bioprint human organs or tissues. Pigmented chitosan objects can be recycled, with the option of reintroducing or discarding the dye at each recycling step, enabling reuse of the polymer independently of colorants. Unlike other plant-based bioplastics (e.g. cellulose, starch), the main natural sources of chitosan come from marine environments and do not compete for land or other human resources. 3D bioprinting of tissue engineering scaffolds for creating artificial tissues and organs is another application where chitosan has gained popularity. Chitosan has high biocompatibility, biodegradability, and antimicrobial, hemostatic, wound healing and immunomodulatory activities which make it suitable for making artificial tissues.
FAD, or flavin adenine dinucleotide, is a prosthetic group (a non-polypeptide unit bound to a protein that is required for function) that consists of an adenine nucleotide and a flavin mononucleotide. FAD is a unique electron acceptor. Its fully reduced form is FADH2 (known as the hydroquinone form), but FAD can also be partially oxidized as FADH by either reducing FAD or oxidizing FADH2. Dehydrogenases typically fully reduce FAD to FADH2. The production of FADH is rare. The double-bonded nitrogen atoms in FAD make it a good acceptor in taking two hydrogen atoms from a substrate. Because it takes two atoms rather than one, FAD is often involved when a double bond is formed in the newly oxidized substrate. FAD is unique because it is reduced by two electrons and two protons, as opposed to both NAD+ and NADP, which only take one proton.
Sources: en.wikipedia.org
Campbell and Satoshi Ōmura; she received it "for her discoveries concerning a novel therapy against Malaria". 2015: American inventor and clean water advocate Deepika Kurup invented a photocatalytic composite material that removes 100% of faecal coliform bacteria from contaminated water. Deepika won the Discovery Education 3M Young Scientist Challenge award and The US Stockholm Junior Water Prize for her work. 2015: Asha de Vos became the first Sri Lankan person to receive a PhD in marine mammal research, completing her thesis on "Factors influencing blue whale aggregations off southern Sri Lanka" at the University of Western Australia. 2016: American geophysicist Marcia McNutt became the first female president of the American National Academy of Sciences. 2016: French-Algerian particle physicist Yasmine Amhis was awarded the Jacques Herbrand Prize given by the French Academy of Sciences 2018: British astrophysicists Hiranya Peiris and Joanna Dunkley and Italian cosmologist Licia Verde were among 27 scientists awarded the Breakthrough Prize in Fundamental Physics for their contributions to "detailed maps of the early universe that greatly improved our knowledge of the evolution of the cosmos and the fluctuations that seeded the formation of galaxies". 2018: British astrophysicist Jocelyn Bell Burnell received the special Breakthrough Prize in Fundamental Physics for her scientific achievements and "inspiring leadership", worth $3 million.
28 April – 2024 Scottish government crisis: BBC News reports that Yousaf has ruled out an electoral pact between the SNP and Alba Party after Alex Salmond suggested the party would support him in a vote of no confidence in the Scottish Parliament. 29 April – 2024 Scottish government crisis: Yousaf announces his resignation as both leader of the SNP and first minister of Scotland when his successor is chosen. 30 April – Officials at Holyrood confirm that Labour's motion of no confidence in the Scottish Government will be voted on by MSPs the next day.
A bursa is a small fluid-filled sac made of white fibrous tissue and lined with synovial membrane. Bursa may also be formed by a synovial membrane that extends outside of the joint capsule. It provides a cushion between bones and tendons or muscles around a joint; bursa are filled with synovial fluid and are found around almost every major joint of the body.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.